3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Breast Neoplasms
57
Carcinoma, Non-Small-Cell Lung
46
Ovarian Neoplasms
31
Stomach Neoplasms
22
Neoplasms
19
Squamous Cell Carcinoma of Head and Neck
18
Lung Neoplasms
18
Neoplasm Metastasis
17
Fallopian Tube Neoplasms
14
Triple Negative Breast Neoplasms
13
Esophageal Neoplasms
13
Esophageal Squamous Cell Carcinoma
10
Colorectal Neoplasms
9
Carcinoma, Ovarian Epithelial
9
Melanoma
8
Head and Neck Neoplasms
8
Endometrial Neoplasms
8
Uterine Cervical Neoplasms
6
Pancreatic Neoplasms
6
Carcinoma, Renal Cell
6
Adenocarcinoma of Lung
6
Urinary Bladder Neoplasms
5
Small Cell Lung Carcinoma
5
Prostatic Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Advanced Solid Tumors
5
Testicular Neoplasms
4
Testicular Germ Cell Tumor
4
Recurrence
4
Carcinoma, Transitional Cell
4
Interventions
pembrolizumab
2
Paclitaxel
2
Carboplatin
2
poly(I).poly(c12,U)
1
liposomal doxorubicin
1
Lenalidomide
1
Interferon alpha-2
1
Gemcitabine
1
Cisplatin
1
Bevacizumab
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Ovarian Cancer Recurrent
×
Paclitaxel
×
Clear all
NCT06843447
2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
460 enrolled
NCT04072263
2021-04-01
OVACURE
Leiden University Medical Center
Phase 1/2
Unknown
12 enrolled